A Multivalent Immunotherapeutic Candidate for
A Multivalent Immunotherapeutic Candidate for
Melanoma
Melanoma
Plasmids (expressed portion)
Peptides
Targets
Melan A
Tyrosinase
NYESO-1
SSX2
MKC1207-D1
Melan A
Tyrosinase
N
O
O
H N
O
N
O
N
O
S
N
O
N
N
O
N
O
O
N
O
O
N
N
O
O
NY-ESO-1 157-165 (L158(Nva), C165V)
MKC1207-P3
165V
N
O
N
H N
O
N
O
O
N
O
O
O
N
O
N
N
O
N
O
N
O
O
N
O
O
SSX2 41-49 (A42V)
MKC1207-P4
MKC1207-D2
158Nva
42V
NYESO-1
SSX2
N
O
O
O
H N
O
N
O
N
O
N
O
N
O
N
O
N
O
N
O
O
N
O
O
melan-a 26-35 (A27Nva)
N
O
O
H N
O
S
N
O
O
O
N
O
N
O
O
N
O
S
N
O
O
N
O
O
N
N
O
O
Tyrosinase 369-377 (V377(Nva))
27Nva
MKC1207-P1
377Nva
MKC1207-P2
A Multivalent Immunotherapeutic Candidate for
A Multivalent Immunotherapeutic Candidate for
Ovarian Carcinoma
Ovarian Carcinoma
Plasmids (expressed portion)
Peptides
Targets
PSMA
PRAME
NYESO-1
SSX2
N
O
N
H N
O
N
O
O
N
O
O
O
N
O
N
N
O
N
O
N
O
O
N
O
O
SSX2 41-49 (A42V)
MKC1106-P4
N
O
O
H N
O
N
O
N
O
S
N
O
N
N
O
N
O
O
N
O
O
N
N
O
O
NY-ESO-1 157-165 (L158(Nva), C165V)
MKC1106-P3
N
O
O
H N
O
N
O
N
O
O
N
N
O
N
N
N
O
N
O
N
O
N
O
O
Prame 425-433 (L426(Nva),433(Nle))
MKC1106-P2
N
O
H N
O
N
O
N
O
O
N
O
N
O
N
O
N
O
N N
N
O
N
O
O
psma 288-297 (I297V)
MKC1106-P1
MKC1106-D1
MKC1106-D2
297V
426Nva
433Nle
158Nva
165V
42V
PRAME
PSMA
NYESO-1
SSX2
A Multivalent Immunotherapeutic
Candidate for Ovarian Carcinoma
NYESO-1
PSMA
0
10
20
30
40
50
60
624.38
624.28
LNCap
Target cells
%
C
y
to
to
xi
c
ity
100:1
30:1
10:1
3:1
0
20
40
60
80
100
Control L158NvaC165V
Peptide boost
%
C
y
to
to
x
ic
it
y
E:T 10
E:T 30
E:T 100
624.38-NYESO
Target cells
PRAME
SSX2
0
10
20
30
40
50
60
70
624.28
624.38
IFN
treated
624.28
IFN
treated
624.38
Target cells
%
C
y
totox
ic
ity
E:T 10
E:T 30
E:T 100
0
20
40
60
80
100
T2 T2+SSX2
41-49
624.28 624.38
Target cells
% Cy
to
to
x
ic
it
y
E:T 10
E:T 30
E:T 100
